Dr Reddy's Laboratories (DRL) has launched the generic version of Astrazeneca's Nexium, used to treat acid reflux, in the US market. (Reuters)
Drug major Dr Reddy’s Laboratories (DRL) has launched the generic version of Astrazeneca’s Nexium, used to treat acid reflux, in the US market.
In a BSE filing, DRL said “it has launched Esomeprazole magnesium delayed release capsules USP, 20 mg and 40 mg, a therapeutic equivalent generic version of Nexium delayed release capsules, in the US market on September 25, following approval from the US Food and Drug Administration.”
Quoting IMS Heath data, the company said Nexium and generic had US sales of approximately USD 5.2 billion for most of recent 12 months ending in July, 2015.
DRL said Esomeprazole capsules are available in bottle count size of 30.
Eesomeprazole is a proton pump inhibitor that decreases the amount of acid produced in the stomach.
DRL shares were trading 5.27 per cent up at Rs 4,181 apiece in morning session on the BSE.